These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31414402)

  • 1. ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.
    Marino R; Perrone J; Nelson LS; Wiegand TJ; Schwarz ES; Wax PM; Stolbach AI
    J Med Toxicol; 2019 Oct; 15(4):307-309. PubMed ID: 31414402
    [No Abstract]   [Full Text] [Related]  

  • 2. Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.
    Andrilla CHA; Coulthard C; Larson EH
    Ann Fam Med; 2017 Jul; 15(4):359-362. PubMed ID: 28694273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine to treat opioid use disorder: A practical guide.
    Nissly T; Levy R
    J Fam Pract; 2018 Jun; 67(9):544-548. PubMed ID: 30216393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between the Number of Certified Buprenorphine Prescribers and the Quantity of Buprenorphine Prescriptions: Evidence from 2015 to 2017.
    Lin LK; Simon K; Hollingsworth A; Saloner B
    J Gen Intern Med; 2019 Nov; 34(11):2313-2315. PubMed ID: 31313114
    [No Abstract]   [Full Text] [Related]  

  • 6. Providing Incentive for Emergency Physician X-Waiver Training: An Evaluation of Program Success and Postintervention Buprenorphine Prescribing.
    Foster SD; Lee K; Edwards C; Pelullo AP; Khatri UG; Lowenstein M; Perrone J
    Ann Emerg Med; 2020 Aug; 76(2):206-214. PubMed ID: 32376089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: An interrupted time series analysis.
    Roy PJ; Suda K; Luo J; Lee M; Anderton J; Olejniczak D; Liebschutz JM
    Int J Drug Policy; 2024 Apr; 126():104381. PubMed ID: 38457960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine X-waiver exemption - beyond the basics for the obstetrical provider.
    Cleary EM; Smid MC; Charles JE; Jones KM; Costantine MM; Saade G; Rood KM
    Am J Obstet Gynecol MFM; 2021 Nov; 3(6):100451. PubMed ID: 34320429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines.
    Jones CM; Olsen Y; Ali MM; Sherry TB; Mcaninch J; Creedon T; Juliana P; Jacobus-Kantor L; Baillieu R; Diallo MM; Thomas A; Gandotra N; Sokolowska M; Ling S; Compton W
    JAMA Health Forum; 2023 Jul; 4(7):e231982. PubMed ID: 37477926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.
    Andrilla CHA; Moore TE; Patterson DG
    J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver.
    Fiscella K; Wakeman SE; Beletsky L
    JAMA Psychiatry; 2019 Mar; 76(3):229-230. PubMed ID: 30586140
    [No Abstract]   [Full Text] [Related]  

  • 12. The End of the X-waiver: Excitement, Apprehension, and Opportunity.
    LeFevre N; St Louis J; Worringer E; Younkin M; Stahl N; Sorcinelli M
    J Am Board Fam Med; 2023 Oct; 36(5):867-872. PubMed ID: 37704389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine Dispensing after Elimination of the Waiver Requirement.
    Chua KP; Bicket MC; Bohnert ASB; Conti RM; Lagisetty P; Nguyen TD
    N Engl J Med; 2024 Apr; 390(16):1530-1532. PubMed ID: 38657250
    [No Abstract]   [Full Text] [Related]  

  • 14. Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
    Qian J; Khatiwada AP; Xue X
    Am J Addict; 2024 May; 33(3):335-338. PubMed ID: 38069608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program.
    Rowe CL; Ahern J; Hubbard A; Coffin PO
    J Subst Abuse Treat; 2022 Jan; 132():108452. PubMed ID: 34098203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
    Andrilla CHA; Moore TE; Patterson DG; Larson EH
    J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empowering Psychiatric Mental Health Nurse Practitioners to Expand Treatment Opportunities for Veterans With Opioid Use Disorder.
    Jones J; Tierney M; Jacobs G; Chien SY; Mallisham S
    J Addict Nurs; 2020; 31(4):261-268. PubMed ID: 33264198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine Prescribing: To Expand or Not to Expand.
    Li X; Shorter D; Kosten TR
    J Psychiatr Pract; 2016 May; 22(3):183-92. PubMed ID: 27123798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine Use in the United States, 2010-2019.
    Thompson MG; Kuriyama A; Yoshino T; Murphy MG; Jackson JL
    Am J Med; 2024 Mar; 137(3):280-283. PubMed ID: 37984777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.